

Thursday 3/12/2026

HCC Meet-the-experts session

09:00-09:45 Registrations

09:45-10:00 Introduction / Objectives

I. Elefsiniotis, G. Germanidis

10:00-11:00 Session I

Moderators: **S. Manolakopoulos, J. Vlachogiannakos**

10:00-10:15 Liver function assessment / NITs use in patients with HCC. **D. Karagiannakis**

10:15-10:30 Portal hypertension management in patients with HCC. **C. Triantos**

10:30-10:45 Prevention and/or management of splachnic thrombosis in patients with HCC. **N. Mathou**

10:45-11:00 Commentators : **B. Minguez, M. Mela, D. Samonakis**

11:00-11:20 Lecture I

Moderators: **M. Deutch, I. Koskinas**

Importance of liver histology in HCC: can it guide therapeutic decisions? **D. Tiniakos**



11:20-12:30 Session II

Moderators: **N. Arkadopoulos, I. Kaklamanos, P. Nahon**

11:20-11:35 Criteria for liver resection in HCC. The ideal patients and the suboptimal candidates. **P. Lykoudis**

11:35-11:50 Conversion Surgery for HCC in the Immunotherapy Era. **Hong Jae Chon**

11:50-12:20 Optimal ablative therapy for early HCC

- The interventional radiologist perspective **N. Ptochis**
- The radiation oncologist perspective **M. Piperis**

12:20-12:30 Commentators: **S. Delis**, **D. Korkolis, G. Kritselis**

12:30-13:00 Lecture II

Moderators: **A. Alexopoulou, S. Ntourakis**

Management of patients with HCC and impaired liver function. **D. Samonakis**

13:00-14:00 Lunch Break

14:00-14:30 Lecture III

Moderators: **I. Elefsiniotis, G. Germanidis**

Hepatocellular Carcinoma: A Changing Landscape in the Era of Immunotherapy
B. Minguez



14:30-15:30	**Session III**
	Moderators: **I. Goulis, B. Minguez, G. Sotiropoulos**
14:30-14:45	Downstaging/downsizing approaches in HCC patients beyond Milan criteria **I. Elefsiniotis**
14:45-15:00	Criteria for liver transplantation in HCC in the era of immunotherapy **E. Cholongitas**
15:00-15:15	Novel strategies in liver transplantation for HCC 2026. **G. Sotiropoulos**
15:15-15:30	Commentators: **Hong Jae Chon, P. Nahon, N. Machairas**
15:30-16:00	**Satellite Lecture**
16:00-16:30	**Coffee Break**
16:30-17:30	**Session IV**
	Moderators: **I. Athanasiadis, H. Gogas, M. Reig**
16:30-16:45	Impact of frequent comorbidities and management of systemic therapy toxicity. **M. Sinakos**
16:45-17:00	Overcoming immunotherapy resistance. **G. Germanidis**
17:00-17:15	Current management of progressive disease under 1st line IO-based treatment. **I. Mpoukovinas**
17:15-17:30	Commentators: **Hong Jae Chon, B. Minguez, P. Nahon**



17:30-19:00	**Case presentations / management / outcomes**
	Moderators: **I. Elefsiniotis, G. Papatheodoridis, G. Sotiropoulos**
17:30-18:00	Case 1. **S. Pantzios**
18:00-18:30	Case 2. **A. Syriha**
18:30-19:00	Case 3 **G. Zogas**
	Commentators: **Hong Jae Chon, B. Minguez, P. Nahon, M. Reig**
19:00-19:30	**State-of-the-art Lecture**
	Moderators: **G. Papatheodoridis, J. Vlachogiannakos**
	Clinical decision-making in HCC: the CUSE approach. **M. Reig**
19.30-20:30	**Opening Ceremony**
	Opening Ceremony Lecture
	The history of liver **D. Tiniakos**

Friday 4/12/2026

10:00-11:00	**Session I: Advances in primary liver cancer imaging**
	Moderators: **S. Benakis, I. Skouras**
10:00-10:15	The added value of contrast-enhanced ultrasonography. **V. Ouranos**
10:15-10:30	Precision imaging in liver MRI. **E. Mainta**
10:30-10:45	Clinical utility of PET-CT scan**. K. Mainta**



10:45-11:00 Commentators : **S. Pantzios, Ch. Triantopoulou**

11:00-12:30 Session II: Management of unusual cases

Moderators: **I. Elefsiniotis, S. Sakellariou, Ch. Triantopoulou**

11:00-11:20 Case 1. **D. Giriki, O. Sidiropoulos**

11:20-11:40 Case 2. **D. Antoniadi, P. Stamopoulos**

11:40-12:00 Case 3. **M. Ioakeim, V. Oreopoulos**

12:00-12:20 Case 4. **M. Malatesta, M. Piperis**

12:20-12:30 Commentators : **D. Stefanou, A. Tasovasili, S. Vrakas**

12.30-13.00 State-of-the-art Lecture

Moderators: **I. Elefsiniotis, G. Germanidis**

Biomarkers of Combination Immunotherapy in Advanced HCC. **Hong Jae Chon**

13:00-13:40 Satellite Lectures

13:40-14:10 Lunch Break

14:10-14:30 Lecture

Moderators: **V. Papadimitropoulos, M. Schina**

MASLD management in 2026 **E. Theocharidou**



14:30-16:10	**Session III: The growing problem of MASLD-HCC**
	Moderators: **V. Sevastianos, E. Skorda, Th. Vassiliadis**
14:30-14:45	Clinical characteristics and outcomes of patients with MASLD **T. Androutsakos**
14:45-15:00	From MASLD to liver carcinogenesis **A. Chatzigeorgiou**
15:00-15:15	Selection of MASLD patients for HCC surveillance **E. Geladari**
15:15-15:30	Pitfalls in HCC surveillance of MASLD patients using US/AFP **G. Zogas**
15:30-15:45	Novel biomarkers/models for HCC surveillance **A. Syriha**
15:45-16:10	Commentators : **G. Kontos, I. Mani, M. Schina**
16:10-16:30	**Satellite Lecture**
16:30-17:00	**Coffee Break**
17:00-18:30	**Session IV: Advances in HCC diagnosis and management**
	Moderators: **I. Elefsiniotis, G. Nasioulas**
17:00-17:20	Clinical impact of microbiome in HCC management. **M. Gazouli**
17:20-17:40	Next generation sequencing (NGS) and HCC. **A. Tsantikidi**
17:40-18:00	Present and future of biopsy in HCC: from tissue to liquid. **B. Minguez**
18:00-18:20	Predictive value of baseline and serially measured ctDNA for OS in patients with HCC receiving first line immunotherapy with Tremelimumab-Durvalumab: preliminary results **S. Pantzios**
18:20-18:30	Commentators : **M. Karamouzis, I. Rapti, Th. Tegos**



18:30-19:00 Lecture

Moderators: **G. Tzimas, C. Vergadis, E. Vezali**

The role of locoregional therapies in the treatment of unresectable HCC in 2026
N. Ptochis

19:00-19:30 Lecture

Moderators: **G. Germanidis, Hong Jae Chon, L. Tzaninis**

Evolving therapies in HCC beyond immunotherapy. **S. Pantzios**

Saturday 5/12/2026

09:00-10:30 Session I: HBP Surgery

Moderators: **I. Kaklamanos, A. Papalois, K. Toutouzas**

09:00-09:40 Current management of resectable intrahepatic cholangiocarcinoma
The surgeon perspective **P. Stamopoulos**
The medical oncologist perspective **M. Theochari**

09:40-10:10 Current management of resectable pancreatic adenocarcinoma
The surgeon perspective **H. Zerbinis**
The medical oncologist perspective **C. Markellos**

10.10-10.30 Commentator : **E. Tagalos**



10:30-11:00	**Lecture**
	Moderators: **A. Lampadariou**
	Liver transplantation for unresectable colorectal liver metastasis in 2026 **S. Kykalos**
11:00-11:30	**Coffee Break**
11:30-12:30	**Session II: Sepsis in patients with solid tumors**
	Moderators: **E. Giamarellos-Bourboulis, P. Myrianthefs**
11:30-11:50	Current sepsis definition. **E. Kyriazopoulou**
11:50-12:10	Management of difficult-to-treat pathogens. **E. Karakike**
12:10-12:30	Immunotherapy of sepsis in patients under cancer immunotherapy. **E. Giamarellos-Bourboulis**
12:30-14:30	**Session III: Clinical emergencies in General Oncology Hospitals**
	Moderators: **E. Diamantis , A. Gavala, I. Grigoriadis**
12:30-12:45	Glycemic control in hospitalized patients. **E. Tzouveli**
12:45-13:00	Real life cases of hyperglycemia / acidosis. **A. Vrelos**
13:00-13:15	Calcium disturbances in hospitalized patients. **E. Sakka**
13:15-13:30	Real life cases of hypo/hypercalcemia **K. Spyropoulou**
13.30-13.45	HPA axis disturbances in the Oncological setting **P. Tzoulis**
13.45-14.00	Real life cases of Cushing and hypopituitarism **P. Tsotras**
14.00-14.30	Commentators : **P. Kouzanidis, K. Stamopoulos, E. Tsigou**



14:30-15:00 Lunch Break

15:00-15:30 Lecture

Moderators: **A. Bisvikis, G. Stamoulis**

Cardiovascular Rehabilitation in Cancer Patients **C. Grassos**

15:30-17:00 Session IV: Clinical challenges arising from the obesity epidemic

Moderators: **G. Argyrakopoulou, P. Grigoropoulos, S. Kostarakou**

15:30-15:50 Abdominal surgery and obesity. **T. Mariolis-Sampsakos**

15:50-16:10 Obesity and cancer. **V. Oraiopoulos**

16:10-16:30 Therapeutic targets in obesity related liver disease. **M. Kalafateli**

16:30-16:50 Diet in sarcopenic obese patients **A. Vadarlis**

16:50-17:00 Commentator : **E. Tzouveli**

17:00-18:30 Session V: Adverse Events Associated with Cancer Immunotherapy

Moderators: **S. Goulas, V. Psalida**

17:00-17:20 Cancer immunotherapy and the respiratory system **S. Kollia**

17:20-17:40 Rheumatologic immune-related manifestations **M. Nitsa**

17:40-18:00 Cancer immunotherapy and the gut **X. Tsamakidis**

18:00-18:20 Cancer immunotherapy and the blood **A. Mpeliani**

18:20-18:30 Commentators: **ES. Tripodaki, R. Zakopoulou**



18:30-19:30 Session VI: Neurology and Cancer

Moderators: **E. Kavvadia, V. Vagenas**

18:30-18:50 Real life cases of paraneoplastic syndrome with neurological manifestation **M. Brinia**

18:50-19:10 Cerebrovascular events in oncologic patients **E. Makri**

19:10-19:30 Cancer chemotherapy/immunotherapy and the nervous system **M. Panagiotou**

19:30-19:40 Commentator: **A. Xampimbi**



ΓΕΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ

Οργάνωση:

ΙΝΣΤΙΤΟΥΤΟ ΜΕΛΕΤΗΣ ΝΕΟΠΛΑΣΜΑΤΩΝ ΠΕΠΤΙΚΟΥ (Ι.Μ.ΝΕ.ΠΕ.)

Επιστημονική Συμμετοχή:

Πανεπιστημιακή Παθολογική Κλινική & Ηπατογαστρεντερολογική Μονάδα

Γ.Ο.Ν.Κ. «Ο ΑΓΙΟΙ ΑΝΑΡΓΥΡΟΙ»

Ημερομηνία Διεξαγωγής:

03-05 Δεκεμβρίου 2026

Τόπος:

Ξενοδοχείο Caravel (αίθουσα Horizon)

Βασιλέως Αλεξάνδρου 2

161 21 Αθήνα

Τηλ. +30 210 7207000

Εγγραφές:

Το κόστος εγγραφής στο Συνέδριο είναι ως εξής:

Ειδικοί ιατροί 100€

Ειδικευόμενοι ιατροί 50€

Λοιποί επαγγελματίες υγείας και

προπτυχιακοί/ μεταπτυχιακοί φοιτητές Δωρεάν

*Οι παραπάνω τιμές είναι πλέον ΦΠΑ



Οδηγίες Φυσικής Παρακολούθησης:

Στους συμμετέχοντες θα σταλεί ηλεκτρονικό badge (barcode), το οποίο θα πρέπει να σκανάρουν κατά την είσοδο και έξοδο τους στην αίθουσα.

Οδηγίες Διαδικτυακής Παρακολούθησης:

Δεν θα υπάρχει ζωντανή αναμετάδοση.

Παραλαβή πιστοποιητικού:

Το πιστοποιητικό παρακολούθησης θα αποσταλεί ηλεκτρονικά, μετά το πέρας των εργασιών του Συνεδρίου, σε όσους συνέδρους παρακολούθησαν το 60% των συνολικών ωρών του επιστημονικού προγράμματος.